Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy.

ABSTRACT: Glioblastoma (GBM) is a highly aggressive and heterogeneous form of brain cancer. Genotypic and phenotypic heterogeneity drives drug resistance and tumor recurrence. Combination chemotherapy could overcome drug resistance; however, GBM's location behind the blood-brain barrier severely limits chemotherapeutic options. Interstitial therapy, delivery of chemotherapy locally to the tumor site, via a biodegradable polymer implant can overcome the blood-brain barrier and increase the range of drugs available for therapy. Ideal drug candidates for interstitial therapy are those that are potent against GBM and work in combination with both standard-of-care therapy and new precision medicine targets. Herein we evaluated paclitaxel for interstitial therapy, investigating the effect of combination w

SUBMITTER: Graham-Gurysh EG 

PROVIDER: S-EPMC7453575 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature